# PeptideScanner evidence objects: Melanotan II

Every published version of the records placed with Melanotan II, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json. Selected public evidence only; not medical advice.

- Objects: 17
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="federal-register-2016-27244-v1"></a>

## Federal Register notice 2016-27244

> The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II.

- Evidence object: `story:federal-register-2016-27244:v1`
- Evidence domain: Regulatory
- Date in source: 2016-11-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-27244/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#federal-register-2016-27244-v1
- Content SHA-256: `dbfc6bc8ea91ed60bbbf2ea219f2be338a0202804477fb242127a854f3c9c215`

### Claims and source pins

#### Headline

Federal Register notice 2016-27244 ([`federal-register-2016-27244-64d472c1e356`](#source-federal-register-2016-27244-64d472c1e356))

#### Summary

The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II. ([`federal-register-2016-27244-64d472c1e356`](#source-federal-register-2016-27244-64d472c1e356))

#### Paragraph 1

The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II. ([`federal-register-2016-27244-64d472c1e356`](#source-federal-register-2016-27244-64d472c1e356))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-27244-64d472c1e356`](#source-federal-register-2016-27244-64d472c1e356))

### Sources

<a id="source-federal-register-2016-27244-64d472c1e356"></a>
- **Federal Register notice 2016-27244 · published 2016-11-14 · Edward Manookian (Also Known as Ed Manning): Debarment Order** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-11-14/pdf/2016-27244.pdf) (`federal-register-2016-27244-64d472c1e356`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-27244." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#federal-register-2016-27244-v1 SHA-256: dbfc6bc8ea91ed60bbbf2ea219f2be338a0202804477fb242127a854f3c9c215.

---

<a id="pubmed-pmid-11035391-melanotan-ii-v1"></a>

## Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.

> PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11035391-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11035391-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-11035391-melanotan-ii-v1
- Content SHA-256: `a84fd67662d0397aa2402afab62914621d3e15f4c79bbc1c82e0770f671aa50b`

### Claims and source pins

#### Headline

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. ([`pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144`](#source-pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144))

#### Summary

PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144`](#source-pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144))

#### Paragraph 1

PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144`](#source-pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144`](#source-pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144))

### Sources

<a id="source-pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144"></a>
- **Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. · retained source version 1:2019-11-04:current:a98ac9bb6144a828b4aa47ec0e3211db7a135f6494ec31fd9a62e0a9cc8f9224** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11035391/) (`pubmed-observation-pmid-11035391-2019-11-04-a98ac9bb6144`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-11035391-melanotan-ii-v1 SHA-256: a84fd67662d0397aa2402afab62914621d3e15f4c79bbc1c82e0770f671aa50b.

---

<a id="pubmed-pmid-1336500-melanotan-ii-v1"></a>

## High-performance liquid chromatographic assay for the alpha-melanotropin\[4,10\] fragment analogue (Melanotan-II) in rat plasma.

> PubMed lists PMID 1336500 in Journal of chromatography as Journal Article, with publication-date metadata of 1992-12-23 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1336500-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1336500-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-1336500-melanotan-ii-v1
- Content SHA-256: `727c38f94eb23f9211ec1b88fe7f70ef0ff6b691fd989ee70114a27ffe40de59`

### Claims and source pins

#### Headline

High-performance liquid chromatographic assay for the alpha-melanotropin\[4,10\] fragment analogue (Melanotan-II) in rat plasma. ([`pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50`](#source-pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50))

#### Summary

PubMed lists PMID 1336500 in Journal of chromatography as Journal Article, with publication-date metadata of 1992-12-23 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50`](#source-pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50))

#### Paragraph 1

PubMed lists PMID 1336500 in Journal of chromatography as Journal Article, with publication-date metadata of 1992-12-23 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50`](#source-pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50`](#source-pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50))

### Sources

<a id="source-pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50"></a>
- **High-performance liquid chromatographic assay for the alpha-melanotropin\[4,10\] fragment analogue (Melanotan-II) in rat plasma. · retained source version 1:2019-06-29:current:ba6819f90c5012ebe907acebc7a6704838984273c29ce04aa0fd4a4252148a35** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1336500/) (`pubmed-observation-pmid-1336500-2019-06-29-ba6819f90c50`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "High-performance liquid chromatographic assay for the alpha-melanotropin\[4,10\] fragment analogue (Melanotan-II) in rat plasma." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-1336500-melanotan-ii-v1 SHA-256: 727c38f94eb23f9211ec1b88fe7f70ef0ff6b691fd989ee70114a27ffe40de59.

---

<a id="pubmed-pmid-19043625-melanotan-ii-v1"></a>

## The first preparative solution phase synthesis of melanotan II.

> PubMed lists PMID 19043625 in Beilstein journal of organic chemistry as Journal Article, with publication-date metadata of 2008-10-30 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19043625-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19043625-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-19043625-melanotan-ii-v1
- Content SHA-256: `ac2e3663974649bbb2c66539105aa03aee187f38b1dd66a0937719fa16cea3de`

### Claims and source pins

#### Headline

The first preparative solution phase synthesis of melanotan II. ([`pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b`](#source-pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b))

#### Summary

PubMed lists PMID 19043625 in Beilstein journal of organic chemistry as Journal Article, with publication-date metadata of 2008-10-30 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b`](#source-pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b))

#### Paragraph 1

PubMed lists PMID 19043625 in Beilstein journal of organic chemistry as Journal Article, with publication-date metadata of 2008-10-30 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b`](#source-pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b`](#source-pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b))

### Sources

<a id="source-pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b"></a>
- **The first preparative solution phase synthesis of melanotan II. · retained source version 1:2021-10-20:current:69d2a3410e2b15fc51aba6dd5e9ee2e53317926c573ce99efc7e2e394d738c55** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19043625/) (`pubmed-observation-pmid-19043625-2021-10-20-69d2a3410e2b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The first preparative solution phase synthesis of melanotan II." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-19043625-melanotan-ii-v1 SHA-256: ac2e3663974649bbb2c66539105aa03aee187f38b1dd66a0937719fa16cea3de.

---

<a id="pubmed-pmid-20965250-melanotan-ii-v1"></a>

## Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery.

> PubMed lists PMID 20965250 in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-10-20 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20965250-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20965250-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-20965250-melanotan-ii-v1
- Content SHA-256: `b9a403c55e996a920bff789b1fb739ca80140209bf7bf756124de8d9eca69304`

### Claims and source pins

#### Headline

Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. ([`pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d`](#source-pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d))

#### Summary

PubMed lists PMID 20965250 in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-10-20 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d`](#source-pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d))

#### Paragraph 1

PubMed lists PMID 20965250 in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-10-20 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d`](#source-pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d`](#source-pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d))

### Sources

<a id="source-pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d"></a>
- **Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. · retained source version 1:2016-11-25:current:5b1308f95d8d0329c90df5bb2f7d7a87c3e979085db3e7f78eb2c2bff3403bcf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20965250/) (`pubmed-observation-pmid-20965250-2016-11-25-5b1308f95d8d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-20965250-melanotan-ii-v1 SHA-256: b9a403c55e996a920bff789b1fb739ca80140209bf7bf756124de8d9eca69304.

---

<a id="pubmed-pmid-24771717-melanotan-ii-v1"></a>

## Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.

> PubMed lists PMID 24771717 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2014-04-25 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24771717-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24771717-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-24771717-melanotan-ii-v1
- Content SHA-256: `5979c1508d0682b93c762cddfc1567d86b91597833fa68b596b99ecef254b33d`

### Claims and source pins

#### Headline

Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. ([`pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55`](#source-pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55))

#### Summary

PubMed lists PMID 24771717 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2014-04-25 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55`](#source-pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55))

#### Paragraph 1

PubMed lists PMID 24771717 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2014-04-25 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55`](#source-pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55`](#source-pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55))

### Sources

<a id="source-pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55"></a>
- **Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. · retained source version 1:2019-12-10:current:35df72d72c5530d0ec1f0b2996d14c233f54e761f5cbf6d2196c6b30c061e10f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24771717/) (`pubmed-observation-pmid-24771717-2019-12-10-35df72d72c55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-24771717-melanotan-ii-v1 SHA-256: 5979c1508d0682b93c762cddfc1567d86b91597833fa68b596b99ecef254b33d.

---

<a id="pubmed-pmid-26108334-melanotan-ii-v1"></a>

## Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.

> PubMed lists PMID 26108334 in Alcoholism, clinical and experimental research as Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2015-06-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26108334-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26108334-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-26108334-melanotan-ii-v1
- Content SHA-256: `27b1937040c576226d3e9c043411344fac04d8d1809f225d60460b5421daa925`

### Claims and source pins

#### Headline

Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. ([`pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110`](#source-pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110))

#### Summary

PubMed lists PMID 26108334 in Alcoholism, clinical and experimental research as Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2015-06-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110`](#source-pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110))

#### Paragraph 1

PubMed lists PMID 26108334 in Alcoholism, clinical and experimental research as Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2015-06-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110`](#source-pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110`](#source-pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110))

### Sources

<a id="source-pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110"></a>
- **Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. · retained source version 1:2019-09-29:current:37ff8c082110cdeabdb7ae18a904ccf2c580b5487b956b89b5897d52bcf54f95** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26108334/) (`pubmed-observation-pmid-26108334-2019-09-29-37ff8c082110`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-26108334-melanotan-ii-v1 SHA-256: 27b1937040c576226d3e9c043411344fac04d8d1809f225d60460b5421daa925.

---

<a id="pubmed-pmid-28905366-melanotan-ii-v1"></a>

## The unregulated use of melanotan-II is of public health interest to Australian dermatologists.

> PubMed lists PMID 28905366 in The Australasian journal of dermatology as Case Reports, Letter, with publication-date metadata of 2017-09-14 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28905366-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-03-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28905366-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-28905366-melanotan-ii-v1
- Content SHA-256: `ea8560c4099c3545fb550f8578daaac8c92f6460fd79160b9158306e1e710c48`

### Claims and source pins

#### Headline

The unregulated use of melanotan-II is of public health interest to Australian dermatologists. ([`pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6`](#source-pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6))

#### Summary

PubMed lists PMID 28905366 in The Australasian journal of dermatology as Case Reports, Letter, with publication-date metadata of 2017-09-14 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6`](#source-pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6))

#### Paragraph 1

PubMed lists PMID 28905366 in The Australasian journal of dermatology as Case Reports, Letter, with publication-date metadata of 2017-09-14 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6`](#source-pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6`](#source-pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6))

### Sources

<a id="source-pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6"></a>
- **The unregulated use of melanotan-II is of public health interest to Australian dermatologists. · retained source version 1:2019-03-14:current:b62d70a3bff6ded6d8a807ec5ae5b1e5eda025c161ab9f4d4ac3239e6a74cbb5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28905366/) (`pubmed-observation-pmid-28905366-2019-03-14-b62d70a3bff6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The unregulated use of melanotan-II is of public health interest to Australian dermatologists." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-28905366-melanotan-ii-v1 SHA-256: ea8560c4099c3545fb550f8578daaac8c92f6460fd79160b9158306e1e710c48.

---

<a id="pubmed-pmid-31953620-melanotan-ii-v1"></a>

## Melanotan II: a possible cause of renal infarction: review of the literature and case report.

> PubMed lists PMID 31953620 in CEN case reports as Case Reports, Journal Article, Review, with publication-date metadata of 2020-01-18 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31953620-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31953620-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-31953620-melanotan-ii-v1
- Content SHA-256: `3c79936e8755c0d6a88b50d0660dc75227283eb3fd65ca8ef5baa8998d1a39d4`

### Claims and source pins

#### Headline

Melanotan II: a possible cause of renal infarction: review of the literature and case report. ([`pubmed-observation-pmid-31953620-2021-06-21-c55812464c83`](#source-pubmed-observation-pmid-31953620-2021-06-21-c55812464c83))

#### Summary

PubMed lists PMID 31953620 in CEN case reports as Case Reports, Journal Article, Review, with publication-date metadata of 2020-01-18 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31953620-2021-06-21-c55812464c83`](#source-pubmed-observation-pmid-31953620-2021-06-21-c55812464c83))

#### Paragraph 1

PubMed lists PMID 31953620 in CEN case reports as Case Reports, Journal Article, Review, with publication-date metadata of 2020-01-18 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31953620-2021-06-21-c55812464c83`](#source-pubmed-observation-pmid-31953620-2021-06-21-c55812464c83))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31953620-2021-06-21-c55812464c83`](#source-pubmed-observation-pmid-31953620-2021-06-21-c55812464c83))

### Sources

<a id="source-pubmed-observation-pmid-31953620-2021-06-21-c55812464c83"></a>
- **Melanotan II: a possible cause of renal infarction: review of the literature and case report. · retained source version 1:2021-06-21:current:c55812464c839830fa26c4e9d21b1ba6c5ab1434377b1bf8174a557d1bce963c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31953620/) (`pubmed-observation-pmid-31953620-2021-06-21-c55812464c83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Melanotan II: a possible cause of renal infarction: review of the literature and case report." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-31953620-melanotan-ii-v1 SHA-256: 3c79936e8755c0d6a88b50d0660dc75227283eb3fd65ca8ef5baa8998d1a39d4.

---

<a id="pubmed-pmid-32674774-melanotan-ii-v1"></a>

## Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II.

> PubMed lists PMID 32674774 in Analytica chimica acta as Journal Article, with publication-date metadata of 2020-05-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32674774-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32674774-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-32674774-melanotan-ii-v1
- Content SHA-256: `f4841c7cfe99d734dc817c7c788e26f85e65d968362e34775af849b7986cf819`

### Claims and source pins

#### Headline

Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II. ([`pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16`](#source-pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16))

#### Summary

PubMed lists PMID 32674774 in Analytica chimica acta as Journal Article, with publication-date metadata of 2020-05-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16`](#source-pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16))

#### Paragraph 1

PubMed lists PMID 32674774 in Analytica chimica acta as Journal Article, with publication-date metadata of 2020-05-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16`](#source-pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16`](#source-pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16))

### Sources

<a id="source-pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16"></a>
- **Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II. · retained source version 1:2021-03-01:current:d8d9a4c61d160c6088f3ba5f73d140f0cec69279c2e243dec162f076422ce37e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32674774/) (`pubmed-observation-pmid-32674774-2021-03-01-d8d9a4c61d16`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-32674774-melanotan-ii-v1 SHA-256: f4841c7cfe99d734dc817c7c788e26f85e65d968362e34775af849b7986cf819.

---

<a id="pubmed-pmid-34464955-melanotan-ii-v1"></a>

## Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

> PubMed lists PMID 34464955 in Dermatology (Basel, Switzerland) as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34464955-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-02-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34464955-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-34464955-melanotan-ii-v1
- Content SHA-256: `a388e1cafc7983d1dd399017dc25d73ee6fe6e7192d4fdac36959a8120891ca2`

### Claims and source pins

#### Headline

Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. ([`pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b`](#source-pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b))

#### Summary

PubMed lists PMID 34464955 in Dermatology (Basel, Switzerland) as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b`](#source-pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b))

#### Paragraph 1

PubMed lists PMID 34464955 in Dermatology (Basel, Switzerland) as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b`](#source-pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b`](#source-pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b))

### Sources

<a id="source-pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b"></a>
- **Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. · retained source version 1:2022-02-15:current:c13661b39e7b667ffa36d866c4f939c6f57d14281f63b1377a0fbca65732008f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34464955/) (`pubmed-observation-pmid-34464955-2022-02-15-c13661b39e7b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Melanotan II User Experience: A Qualitative Study of Online Discussion Forums." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-34464955-melanotan-ii-v1 SHA-256: a388e1cafc7983d1dd399017dc25d73ee6fe6e7192d4fdac36959a8120891ca2.

---

<a id="pubmed-pmid-35188390-melanotan-ii-v1"></a>

## CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.

> PubMed lists PMID 35188390 in Journal of medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-21 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35188390-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35188390-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-35188390-melanotan-ii-v1
- Content SHA-256: `9265473b1076673835e4d2086deb58f3860a8f18ace2310817a1ccb253350b4e`

### Claims and source pins

#### Headline

CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. ([`pubmed-observation-pmid-35188390-2026-03-07-725261757d1f`](#source-pubmed-observation-pmid-35188390-2026-03-07-725261757d1f))

#### Summary

PubMed lists PMID 35188390 in Journal of medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-21 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35188390-2026-03-07-725261757d1f`](#source-pubmed-observation-pmid-35188390-2026-03-07-725261757d1f))

#### Paragraph 1

PubMed lists PMID 35188390 in Journal of medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-21 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35188390-2026-03-07-725261757d1f`](#source-pubmed-observation-pmid-35188390-2026-03-07-725261757d1f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35188390-2026-03-07-725261757d1f`](#source-pubmed-observation-pmid-35188390-2026-03-07-725261757d1f))

### Sources

<a id="source-pubmed-observation-pmid-35188390-2026-03-07-725261757d1f"></a>
- **CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. · retained source version 1:2026-03-07:current:725261757d1f5058f95696de5a796fcac7912bd2cffef0991b458401e83c3ffc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35188390/) (`pubmed-observation-pmid-35188390-2026-03-07-725261757d1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-35188390-melanotan-ii-v1 SHA-256: 9265473b1076673835e4d2086deb58f3860a8f18ace2310817a1ccb253350b4e.

---

<a id="pubmed-pmid-38285527-melanotan-ii-v1"></a>

## 5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.

> PubMed lists PMID 38285527 in Chemistry (Weinheim an der Bergstrasse, Germany) as Journal Article, with publication-date metadata of 2024-02-15 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38285527-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-04-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38285527-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-38285527-melanotan-ii-v1
- Content SHA-256: `d8f3c297842f3d43412b9b2f2fe8ba1d97d8122a6f8207d44b03ddf3fd6b29c6`

### Claims and source pins

#### Headline

5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II. ([`pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f`](#source-pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f))

#### Summary

PubMed lists PMID 38285527 in Chemistry (Weinheim an der Bergstrasse, Germany) as Journal Article, with publication-date metadata of 2024-02-15 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f`](#source-pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f))

#### Paragraph 1

PubMed lists PMID 38285527 in Chemistry (Weinheim an der Bergstrasse, Germany) as Journal Article, with publication-date metadata of 2024-02-15 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f`](#source-pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f`](#source-pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f))

### Sources

<a id="source-pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f"></a>
- **5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II. · retained source version 1:2024-04-08:current:64b0ef94d28ffd0dfaf5c4febf35993ed2729d22dcbfbc0d68da789cb3b7c156** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38285527/) (`pubmed-observation-pmid-38285527-2024-04-08-64b0ef94d28f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-38285527-melanotan-ii-v1 SHA-256: d8f3c297842f3d43412b9b2f2fe8ba1d97d8122a6f8207d44b03ddf3fd6b29c6.

---

<a id="pubmed-pmid-7981427-melanotan-ii-v1"></a>

## A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.

> PubMed lists PMID 7981427 in Biopharmaceutics & drug disposition as Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-07 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7981427-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-10-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7981427-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-7981427-melanotan-ii-v1
- Content SHA-256: `1d7a612373f3baee32c2fec1619e381838ea6fa94950f5c96a06b62b7bef0c59`

### Claims and source pins

#### Headline

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. ([`pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e`](#source-pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e))

#### Summary

PubMed lists PMID 7981427 in Biopharmaceutics & drug disposition as Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-07 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e`](#source-pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e))

#### Paragraph 1

PubMed lists PMID 7981427 in Biopharmaceutics & drug disposition as Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-07 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e`](#source-pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e`](#source-pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e))

### Sources

<a id="source-pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e"></a>
- **A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. · retained source version 1:2019-10-23:current:7297c92a878ef77f6081c0bb8a2e5266b13c96530863bec690946f53f9a3f1ff** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7981427/) (`pubmed-observation-pmid-7981427-2019-10-23-7297c92a878e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-7981427-melanotan-ii-v1 SHA-256: 1d7a612373f3baee32c2fec1619e381838ea6fa94950f5c96a06b62b7bef0c59.

---

<a id="pubmed-pmid-8637402-melanotan-ii-v1"></a>

## Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.

> PubMed lists PMID 8637402 in Life sciences as Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8637402-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8637402-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-8637402-melanotan-ii-v1
- Content SHA-256: `226b50f7f4eab3ab086d5c630630b494b3f10454d836a092f7d0a067235f6405`

### Claims and source pins

#### Headline

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ([`pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd`](#source-pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd))

#### Summary

PubMed lists PMID 8637402 in Life sciences as Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd`](#source-pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd))

#### Paragraph 1

PubMed lists PMID 8637402 in Life sciences as Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd`](#source-pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd`](#source-pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd))

### Sources

<a id="source-pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd"></a>
- **Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. · retained source version 1:2019-07-01:current:9802ba03cabd3b4358de7d7ef2b98ae8cd4e64109b4620f7590a37b45dad85fb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8637402/) (`pubmed-observation-pmid-8637402-2019-07-01-9802ba03cabd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-8637402-melanotan-ii-v1 SHA-256: 226b50f7f4eab3ab086d5c630630b494b3f10454d836a092f7d0a067235f6405.

---

<a id="pubmed-pmid-9050812-melanotan-ii-v1"></a>

## Systemic delivery of melanotan II through the ocular route in rabbits.

> PubMed lists PMID 9050812 in Journal of pharmaceutical sciences as Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9050812-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2006-04-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9050812-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-9050812-melanotan-ii-v1
- Content SHA-256: `8a0aab90e7e6a33b1f912cf4aa5a4679d7c081048f33642975a47b52d25118bd`

### Claims and source pins

#### Headline

Systemic delivery of melanotan II through the ocular route in rabbits. ([`pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9`](#source-pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9))

#### Summary

PubMed lists PMID 9050812 in Journal of pharmaceutical sciences as Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9`](#source-pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9))

#### Paragraph 1

PubMed lists PMID 9050812 in Journal of pharmaceutical sciences as Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9`](#source-pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9`](#source-pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9))

### Sources

<a id="source-pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9"></a>
- **Systemic delivery of melanotan II through the ocular route in rabbits. · retained source version 1:2006-04-13:current:4a1cc225ada909cedc8012787127ebacfb569412df52646adb986837090f9931** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9050812/) (`pubmed-observation-pmid-9050812-2006-04-13-4a1cc225ada9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Systemic delivery of melanotan II through the ocular route in rabbits." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-9050812-melanotan-ii-v1 SHA-256: 8a0aab90e7e6a33b1f912cf4aa5a4679d7c081048f33642975a47b52d25118bd.

---

<a id="pubmed-pmid-9106033-melanotan-ii-v1"></a>

## Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography.

> PubMed lists PMID 9106033 in Journal of chromatography. B, Biomedical sciences and applications as Journal Article, with publication-date metadata of 1997-03-07 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9106033-melanotan-ii:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9106033-melanotan-ii/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-9106033-melanotan-ii-v1
- Content SHA-256: `9624e71cace99589256c76d71c64eeca26e81ff7c01748bfc49fb56ec1cc1946`

### Claims and source pins

#### Headline

Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography. ([`pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5`](#source-pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5))

#### Summary

PubMed lists PMID 9106033 in Journal of chromatography. B, Biomedical sciences and applications as Journal Article, with publication-date metadata of 1997-03-07 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5`](#source-pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5))

#### Paragraph 1

PubMed lists PMID 9106033 in Journal of chromatography. B, Biomedical sciences and applications as Journal Article, with publication-date metadata of 1997-03-07 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5`](#source-pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5`](#source-pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5))

### Sources

<a id="source-pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5"></a>
- **Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography. · retained source version 1:2019-08-31:current:6632b4c968d53f6473cec015f5fa67e43dc1d75ed6b89616eda2093e513b9316** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9106033/) (`pubmed-observation-pmid-9106033-2019-08-31-6632b4c968d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/melanotan-ii.json#pubmed-pmid-9106033-melanotan-ii-v1 SHA-256: 9624e71cace99589256c76d71c64eeca26e81ff7c01748bfc49fb56ec1cc1946.

